Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

TOMI™ Environmental Solutions, Inc. Announces New Sales Leadership


Posted on: 02 May 18

BEVERLY HILLS, Calif., May 02, 2018 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc. (“TOMI”) (OTCQX:TOMZ), a global provider of infection prevention and decontamination products, services and research, including SteraMist™, a hydrogen peroxide-based mist and fog registered as Binary Ionization Technology® (BIT™) with the U.S. Environmental Protection Agency (“EPA”) for use as a hospital-healthcare disinfectant, and general disinfectant, including C. diff, h1n1, norovirus, salmonella and MRSA, announced today that Stephen Grant, a senior leader in both the bio-tech and medical markets, will direct all sales efforts across all divisions.

In his role as Vice President of Sales, he will bring his 30 plus years' experience to manage business development for national sales teams and manufacturing representatives in Life Sciences, Hospital-HealthCare, the TOMI Service Network and Food Safety divisions of the company.

Among previous positions held, he was a Vice President in the Life Science Division/Americas Sales and Marketing for over two years at Bioquell Inc (USA) and has extensive knowledge of hydrogen peroxide products as decontamination methods in a variety of divisions and verticals. This made him a natural fit for his new role at TOMI.

Mr. Grant shared, “I am really excited to be part of TOMI and expanding the use of SteraMist™ across all divisions. I am confident in my ability to direct the resources already in place to meet and exceed projected financial goals. SteraMist™ has an excellent reputation in the life sciences, services and hospital markets and I intend to turn that brand awareness into winning more sales opportunities.”

Dr. Halden Shane, TOMI’s CEO, stated, “The addition of such a seasoned and successful sales leader will position SteraMist™ to secure the lead against other competing technologies currently available. Steve believes the efficacy and efficiency of SteraMist™ make it the best disinfection / decontamination solution on the market. This confidence in the product line should result in TOMI achieving significant growth in 2018.”

About TOMI Environmental Solutions, Inc.

TOMI™ Environmental Solutions, Inc. (OTCQX:TOMZ) is a global decontamination and infection prevention company, providing environmental solutions for indoor surface disinfection through manufacturing, sales and licensing of its premier Binary Ionization Technology® (BIT™) platform, which was invented under a defense grant in association with the Defense Advanced Research Projects Agency (DARPA) of the U.S. Department of Defense. BIT™ uses a low percentage Hydrogen Peroxide as its only active ingredient to produce a hydroxyl radical (.OH ion), known as Ionized Hydrogen Peroxide (iHP™), represented by the TOMI™ SteraMist™ brand of products, which produces a germ-killing aerosol that works like a visual non-caustic gas.

TOMI’s™ products are designed to service a broad spectrum of commercial structures, including but not limited to hospitals and medical facilities, cruise ships, office buildings, hotel and motel rooms, schools, restaurants, meat and produce processing facilities, military barracks, police and fire departments, and athletic facilities. TOMI’s™ products and services have also been used in single-family homes and multi-unit residences.

TOMI™ also develops training programs and application protocols for its clients and is a member in good standing of The American Biological Safety Association, The American Association of Tissue Banks, Association for Professionals in Infection Control and Epidemiology, Society for Healthcare Epidemiology of America and The Restoration Industry Association.

For additional information, please visit http://www.tomimist.com/ or contact us at info@tomimist.com.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995

Certain written and oral statements made by us may constitute “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 (the “Reform Act”). Forward-looking statements are identified by such words and phrases as “we expect,” “expected to,” “estimates,” “estimated,” “current outlook,” “we look forward to,” “would equate to,” “projects,” “projections,” “projected to be,” “anticipates,” “anticipated,” “we believe,” “could be,” and other similar phrases. All statements addressing operating performance, events, or developments that we expect or anticipate will occur in the future, including statements relating to revenue growth, earnings, earnings-per-share growth, or similar projections, are forward-looking statements within the meaning of the Reform Act. They are forward-looking, and they should be evaluated in light of important risk factors that could cause our actual results to differ materially from our anticipated results. The information provided in this document is based upon the facts and circumstances known at this time. We undertake no obligation to update these forward-looking statements after the date of this release

MEDIA RELATIONS CONTACT

Juliana deRosa
Vice President of Domestic Operations
jderosa@tomimist.com

GlobeNewswire
globenewswire.com

Last updated on: 02/05/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.